Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40261-022-01183-1DOI Listing

Publication Analysis

Top Keywords

clinical response
4
response futibatinib
4
futibatinib patients
4
patients high-level
4
high-level fgfr2-amplified
4
fgfr2-amplified advanced
4
advanced gastric
4
gastric cancer
4
cancer case
4
case reports
4

Similar Publications

Background: Breast cancer treatment, particularly during the perioperative period, is often accompanied by significant psychological distress, including anxiety and uncertainty. Mobile health (mHealth) interventions have emerged as promising tools to provide timely psychosocial support through convenient, flexible, and personalized platforms. While research has explored the use of mHealth in breast cancer prevention, care management, and survivorship, few studies have examined patients' experiences with mobile interventions during the perioperative phase of breast cancer treatment.

View Article and Find Full Text PDF

Retinol binding protein 4 (RBP4), the circulating carrier of retinol, complexes with transthyretin (TTR) and is a potential biomarker of cardiometabolic disease. However, RBP4 quantitation relies on immunoassays and Western blots without retinol and TTR measurement. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous absolute quantitation of circulating RBP4 and TTR is critical to establishing their biomarker potential.

View Article and Find Full Text PDF

Systemic Delivery of an mRNA-Encoding, Tumor-Activated Interleukin-12 Lock to Eliminate Tumors and Avoid Immune-Related Adverse Events.

Nano Lett

September 2025

Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha 410082, China.

Interleukin-12 (IL-12) is a robust proinflammatory cytokine that activates immune cells, such as T cells and natural killer cells, to induce antitumor immunity. However, the clinical application of recombinant IL-12 has been limited by systemic immune-related adverse events (irAEs) and rapid degradation. To address these challenges, we employed mRNA technology to encode a tumor-activated IL-12 "lock" fusion protein that offers both therapeutic efficacy and systemic safety.

View Article and Find Full Text PDF

Background: Peripheral nerve injury commonly results in pain and long-term disability for patients. Recovery after in-continuity stretch or crush injury remains inherently unpredictable. However, surgical intervention yields the most favorable outcomes when performed shortly after injury.

View Article and Find Full Text PDF